Insmed (INSM) Other Non-Current Liabilities (2011 - 2026)
Insmed (INSM) recorded quarterly Other Non-Current Liabilities of $5.7 million in Q1 2026, down 98.19% quarter-over-quarter from $314.3 million in Q4 2025, and down 96.96% on a YoY basis from $187.2 million in Q1 2025.
Insmed (INSM) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Insmed's Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 96.96% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (down 96.96% YoY), while the FY2025 annual figure was $314.3 million, up 86.11% from the prior year.
- Other Non-Current Liabilities was $5.7 million for Q1 2026 at Insmed, down from $314.3 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $314.3 million in Q4 2025 to a low of $5.6 million in Q2 2025.
- Historically, Other Non-Current Liabilities has averaged $76.7 million across 5 years, with a median of $60.5 million in 2022.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Liabilities surged 1043.24% in 2023, then sank 96.96% in 2026.
- A 5-year view of Other Non-Current Liabilities shows it stood at $7.4 million in 2022, then soared by 1043.24% to $84.6 million in 2023, then soared by 99.65% to $168.9 million in 2024, then jumped by 86.11% to $314.3 million in 2025, then plunged by 98.19% to $5.7 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $5.7 million (Q1 2026), $314.3 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Insmed | 19.79 Bn | 18.57 Bn | 258.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.68 Mn |
| Dec 31, 2025 | 314.34 Mn |
| Sep 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 5.56 Mn |
| Mar 31, 2025 | 187.20 Mn |
| Dec 31, 2024 | 168.90 Mn |
| Jun 30, 2024 | 12.40 Mn |
| Mar 31, 2024 | 73.40 Mn |
| Dec 31, 2023 | 84.60 Mn |
| Sep 30, 2023 | 69.90 Mn |
| Jun 30, 2023 | 61.70 Mn |
| Mar 31, 2023 | 49.80 Mn |
| Dec 31, 2022 | 7.40 Mn |
| Sep 30, 2022 | 59.30 Mn |
| Jun 30, 2022 | 55.60 Mn |
| Mar 31, 2022 | 66.12 Mn |
| Dec 31, 2021 | 75.67 Mn |
| Sep 30, 2021 | 23.88 Mn |
| Jun 30, 2021 | 12.81 Mn |
| Mar 31, 2021 | 9.30 Mn |